JPRN-UMIN000007141已完成2 期
Multicenter Phase II Clinical Study of the Safety and Efficacy of Discontinuing Nilotinib Treatment in Patients with Chronic Phase Chronic Myelogenous Leukemia Who Have Achieved Complete Molecular Response with Imatinib or Nilotinib - Stop Nilotinib trial (NILSt trial)
Cooperative study between the West Japan Hematology Study Group and the Clinical Research Support Center Kyushu0 个研究点目标入组 120 人开始时间: 2012年2月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients previously treated by tyrosine kinase inhibitors other than imatinib or nilotinib. 2) Patients confirmed to have the T315I point mutation of BCR-ABL. 3) Patients with a history of hematopoietic stem cell transplantation. 4) Patients with cardiovascular dysfunction. 5) Pregnant women or those with suspected pregnancy. Nursing women and those who plan to become pregnant during the study period.
研究者
相似试验
招募中
2 期
Study of KTE-X19 in Adult Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaJPRN-jRCT2063230095Asou Hiroya21
进行中（未招募）
1 期
A Phase 1/2 Multicenter Study of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.Relapsed/Refractory Chronic Lymphocytic LeukemiaMedDRA version: 20.0Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864EUCTR2018-001923-38-DEKite Pharma, Inc16
进行中（未招募）
1 期
A Phase 1/2 Multicenter Study of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.EUCTR2018-001923-38-ITKITE PHARMA INC.108
进行中（未招募）
1 期
A Phase 1/2 Multicenter Study of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.Relapsed/Refractory Chronic Lymphocytic LeukemiaMedDRA version: 20.0Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864EUCTR2018-001923-38-ESKite Pharma, Inc108
进行中（未招募）
1 期
A Phase 1/2 Multicenter Study of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.Relapsed/Refractory Chronic Lymphocytic LeukemiaMedDRA version: 21.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864EUCTR2018-001923-38-GBKite Pharma, Inc16